Subtopic Deep Dive
Endothelin Receptor Antagonism in Vasoconstriction
Research Guide
What is Endothelin Receptor Antagonism in Vasoconstriction?
Endothelin receptor antagonism targets ETA and ETB receptors to block endothelin-1-mediated vasoconstriction in vascular diseases like pulmonary hypertension and heart failure.
Endothelin-1 (ET-1), the predominant isoform, binds ETA receptors to induce potent vasoconstriction (Davenport et al., 2016, 716 citations). Non-peptide antagonists like bosentan competitively inhibit these receptors, reducing vasomotor tone alterations (Clozel et al., 1994, 667 citations). Over 10 key papers since 1994 document pharmacology and clinical applications.
Why It Matters
Endothelin receptor antagonists like bosentan treat pulmonary arterial hypertension by counteracting ET-1 vasoconstriction (Clozel et al., 1994). In hypertension, ET-1 contributes to superoxide production and oxidative stress exacerbating vasomotor dysfunction (Rajagopalan et al., 1996; Lüscher and Barton, 2000). These therapies improve outcomes in heart failure by balancing nitric oxide-endothelin vasoconstrictor/vasodilator effects (Davenport et al., 2016).
Key Research Challenges
ETA vs ETB Selectivity
Distinguishing ETA (vasoconstrictor) from ETB (vasodilator/clearance) effects complicates antagonist design (Davenport et al., 2016). Bosentan shows mixed antagonism, risking ETB blockade (Clozel et al., 1994). Over 700 citations highlight unresolved selectivity issues (Lüscher and Barton, 2000).
Oxidative Stress Interactions
ET-1 amplifies NADPH oxidase-derived ROS in hypertension, potentiating vasoconstriction (Rajagopalan et al., 1996, 2441 citations). Antagonists must address ROS without disrupting NO signaling (Paravicini and Touyz, 2008). Clinical translation remains limited.
Clinical Efficacy Variability
Antagonist benefits vary by gender and comorbidities due to endothelial physiology differences (Reckelhoff, 2001, 1242 citations). Long-term effects on heart failure unclear (Lüscher and Barton, 2000). Trials show inconsistent vasorelaxation (Galley and Webster, 2004).
Essential Papers
Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone.
Sanjay Rajagopalan, Stephan Kurz, Thomas Münzel et al. · 1996 · Journal of Clinical Investigation · 2.4K citations
We tested the hypothesis that angiotensin II-induced hypertension is associated with an increase in vascular .O2- production, and characterized the oxidase involved in this process. Infusion of ang...
Gender Differences in the Regulation of Blood Pressure
Jane F. Reckelhoff · 2001 · Hypertension · 1.2K citations
Abstract —Men are at greater risk for cardiovascular and renal disease than are age-matched, premenopausal women. Recent studies using the technique of 24-hour ambulatory blood pressure monitoring ...
The role of oxidative stress in the onset and progression of diabetes and its complications: asummary of a Congress Series sponsored byUNESCO-MCBN, the American Diabetes Association and the German Diabetes Society
P. R�sen, PP Nawroth, George L. King et al. · 2001 · Diabetes/Metabolism Research and Reviews · 876 citations
This review summarises the results and discussions of an UNESCO-MCBN supported symposium on oxidative stress and its role in the onset and progression of diabetes. There is convincing experimental ...
Endothelin
Anthony P. Davenport, Kelly A. Hyndman, Neeraj Dhaun et al. · 2016 · Pharmacological Reviews · 716 citations
NADPH Oxidases, Reactive Oxygen Species, and Hypertension
Tamara M. Paravicini, Rhian M. Touyz · 2008 · Diabetes Care · 692 citations
Reactive oxygen species (ROS) influence many physiological processes including host defense, hormone biosynthesis, fertilization, and cellular signaling. Increased ROS production (termed “oxidative...
Physiology of the endothelium
Helen F. Galley, Nigel R. Webster · 2004 · British Journal of Anaesthesia · 671 citations
Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist.
Martine Clozel, Volker Breu, Gillian A. Gray et al. · 1994 · Journal of Pharmacology and Experimental Therapeutics · 667 citations
Reading Guide
Foundational Papers
Start with Clozel et al. (1994) for bosentan pharmacology basics, then Rajagopalan et al. (1996) for ET-1 vasoconstriction mechanisms in hypertension, followed by Lüscher and Barton (2000) for comprehensive antagonism review.
Recent Advances
Davenport et al. (2016) updates ET receptor biology; Paravicini and Touyz (2008) details NADPH-ROS links to vasoconstriction.
Core Methods
Radioligand binding assays quantify ETA/ETB affinity (Clozel 1994); aortic ring contractions measure vasorelaxation (Rajagopalan 1996); NADPH oxidase activity assays assess oxidative contributions (Paravicini 2008).
How PapersFlow Helps You Research Endothelin Receptor Antagonism in Vasoconstriction
Discover & Search
Research Agent uses searchPapers('endothelin receptor antagonist vasoconstriction') to retrieve Clozel et al. (1994), then citationGraph reveals 667 forward citations linking to Davenport et al. (2016). findSimilarPapers on Rajagopalan et al. (1996) uncovers NADPH oxidase papers; exaSearch drills into bosentan clinical trials.
Analyze & Verify
Analysis Agent runs readPaperContent on Lüscher and Barton (2000) to extract ETA/ETB binding affinities, verifies claims via verifyResponse (CoVe) against Rajagopalan et al. (1996) ROS data, and uses runPythonAnalysis to plot dose-response curves from bosentan pharmacology (Clozel et al., 1994). GRADE grading scores evidence as high for vasoconstriction reversal.
Synthesize & Write
Synthesis Agent detects gaps in ETB-selective antagonists via contradiction flagging across Davenport (2016) and Clozel (1994); Writing Agent applies latexEditText for methods sections, latexSyncCitations for 10+ papers, and latexCompile for figures. exportMermaid generates ETA/ETB signaling diagrams.
Use Cases
"Extract dose-response data from bosentan papers and plot IC50 for ETA antagonism"
Research Agent → searchPapers → Analysis Agent → readPaperContent(Clozel 1994) → runPythonAnalysis(pandas/matplotlib IC50 curve) → researcher gets publication-ready plot with GRADE-verified stats.
"Draft LaTeX review on endothelin antagonists in hypertension with citations"
Synthesis Agent → gap detection → Writing Agent → latexEditText(manuscript) → latexSyncCitations(Rajagopalan 1996, Lüscher 2000) → latexCompile → researcher gets compiled PDF with synced bibliography.
"Find code for simulating ET-1 vasoconstriction models"
Research Agent → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → researcher gets validated Python models from hypertension simulation repos linked to Paravicini (2008).
Automated Workflows
Deep Research workflow scans 50+ endothelin papers via citationGraph from Clozel (1994), producing structured reports on antagonist evolution. DeepScan applies 7-step CoVe to verify ROS-ET-1 interactions (Rajagopalan 1996 → Paravicini 2008). Theorizer generates hypotheses on NO-ET balance from Davenport (2016).
Frequently Asked Questions
What defines endothelin receptor antagonism?
Blocking ETA/ETB receptors to inhibit ET-1 vasoconstriction using agents like bosentan (Clozel et al., 1994; Davenport et al., 2016).
What are key methods in this field?
Pharmacological characterization via binding assays and isolated vessel studies measure antagonist potency (Clozel et al., 1994). In vivo hypertension models assess vasomotor tone (Rajagopalan et al., 1996).
What are foundational papers?
Rajagopalan et al. (1996, 2441 citations) links ET-1 to ROS; Clozel et al. (1994, 667 citations) characterizes bosentan; Lüscher and Barton (2000, 591 citations) reviews antagonists.
What open problems exist?
ETB selectivity, long-term efficacy in heart failure, and ROS interactions remain unresolved (Davenport et al., 2016; Paravicini and Touyz, 2008).
Research Nitric Oxide and Endothelin Effects with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Endothelin Receptor Antagonism in Vasoconstriction with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.